In this study, we quantitatively evaluated the safety profile of PCSK9 inhibitors in real-world settings from an age- and gender-oriented perspective using data from the FAERS database, and compared their risks of cognitive impairment, musculoskeletal disorders and diabetes with various statins and ezetimibe, where PCSK9 inhibitors performed satisfactorily overall. The gene discussed is PCSK9; the disease is musculoskeletal system disorder.